Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.
Vadhan-Raj S, McNamara MG, Venerito M, Riess H, O'Reilly EM, Overman MJ, Zhou X, Vijapurkar U, Kaul S, Wildgoose P, Khorana AA. Vadhan-Raj S, et al. Among authors: wildgoose p. Cancer Med. 2020 Sep;9(17):6196-6204. doi: 10.1002/cam4.3269. Epub 2020 Jul 14. Cancer Med. 2020. PMID: 32663379 Free PMC article. Clinical Trial.
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Khorana AA, et al. Among authors: wildgoose p. N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630. N Engl J Med. 2019. PMID: 30786186 Clinical Trial.
Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial.
Khorana AA, McNamara MG, Kakkar AK, Streiff MB, Riess H, Vijapurkar U, Kaul S, Wildgoose P, Soff GA; CASSINI Investigators. Khorana AA, et al. Among authors: wildgoose p. TH Open. 2020 May 23;4(2):e107-e112. doi: 10.1055/s-0040-1712143. eCollection 2020 Apr. TH Open. 2020. PMID: 32462111 Free PMC article.
Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.
Khorana AA, Berger JS, Wells PS, Seheult R, Ashton V, Laliberté F, Crivera C, Lejeune D, Schein J, Wildgoose P, Lefebvre P, Kaatz S. Khorana AA, et al. Among authors: wildgoose p. Clin Ther. 2017 Jul;39(7):1396-1408. doi: 10.1016/j.clinthera.2017.05.357. Epub 2017 Jun 20. Clin Ther. 2017. PMID: 28645879
Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial.
Mones JV, Streiff MB, Khorana AA, Bendheim GA, Damaraju CV, Wildgoose P, Burton P, Riess H, Soff GA. Mones JV, et al. Among authors: wildgoose p. Res Pract Thromb Haemost. 2021 Jul 20;5(5):e12549. doi: 10.1002/rth2.12549. eCollection 2021 Jul. Res Pract Thromb Haemost. 2021. PMID: 34308096 Free PMC article.
Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?
Coleman CI, Fermann GJ, Weeda ER, Wells PS, Ashton V, Crivera C, Bunz TJ, Wildgoose P, Schein JR, Peacock WF. Coleman CI, et al. Among authors: wildgoose p. Clin Appl Thromb Hemost. 2017 Oct;23(7):830-837. doi: 10.1177/1076029616661415. Epub 2016 Aug 1. Clin Appl Thromb Hemost. 2017. PMID: 27481875 Free article.
66 results